Biological Allograft Chain Tissue Implant

The Biological Allograft Chain Tissue Implant & Associated Manual Surgical Instrumentation: A Prospective, Post-Market Study

A prospective, multi-center study evaluating allograft tissue as a bone void filler when implanted with Lenoss Medical manual surgical instrumentation in patients with painful vertebral compression fractures.

Study Overview

• Status: Recruiting
• Conditions: Vertebral Body Compression Fracture(s)
• Intervention / Treatment: Procedure: Vertebral Body Augmentation; Device: Manual Surgical Instruments

Detailed Description

Vertebral compression fractures can be associated with instability and severe, persistent pain and limitation of activities. This post market study is being conducted to assess fracture stability over time.

• Study Type: Interventional
• Enrollment (Anticipated): 26
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Dom Messerli; Phone Number: 484-988-0477; Email: dom.messerli@lenoss.com

Study Locations

• United States
  • Colorado
    • Denver, Colorado, United States, 80204
      • Recruiting
      • University of Colorado Denver | Anschutz Medical Campus
      • Contact: Nicola Haakonsen; Phone Number: 720-848-2425; Email: Nicola.Haakonsen@cuanschutz.edu
      • Principal Investigator: Corey Ho, MD
  • New York
    • Bronx, New York, United States, 10467
      • Recruiting
      • Montefiore Medical Center
      • Contact: Parina Shah; Phone Number: 718-920-6267; Email: parishah@montefiore.org
      • Principal Investigator: Allan Brook, MD
    • Manhasset, New York, United States, 11030
      • Recruiting
      • North Shore University Hospital
      • Contact: Brittany Hobbie; Phone Number: 516-693-3976; Email: bhobbie@northwell.edu
      • Principal Investigator: Athos Patsalides, MD
    • New York, New York, United States, 10029
      • Recruiting
      • Mount Sinai
      • Principal Investigator: Reade De Leacy, MD
      • Contact: Sukaina Davdani; Phone Number: 212-241-2524; Email: sukaina.davdani@mountsinai.org
  • Oklahoma
    • Edmond, Oklahoma, United States, 73013
      • Active, not recruiting
      • Clinical Investigations LLC

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 50 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. Skeletally mature adult ≥ 50 years of age at the time of surgery;
2. Currently in an independent living environment;
3. One- or two- level, acute (within six weeks of injury), thoracic or lumbar (T6-L5) vertebral body compression fracture(s) with evidence of marrow edema by MRI/CT;
4. Adequate vertebral body height and geometry for insertion of the access instruments, as determined by the investigator and suitable candidate for standard kyphoplasty or vertebroplasty procedure;
5. VAS back pain score ≥ 70 mm on a 100 mm scale;
6. Has central pain over the spinous process upon palpation at the planned vertebral index level;
7. Has failed prior non-surgical medical management (i.e. - physical therapy, narcotic and/or non-narcotic medication)
8. Psychosocially, mentally and physically able to fully comply with this protocol including adhering to scheduled visits, treatment plan, completing forms, and other study procedures;
9. Personally signed and dated informed consent document prior to any study-related procedures indicating that the patient has been informed of all pertinent aspects of the study.

Exclusion Criteria:

1. More than two levels with a vertebral compression fracture;
2. Previous treated or untreated vertebral compression fracture at the to be treated level(s);
3. Uncorrectable coagulopathy;
4. Previous instrumented spinal surgery;
5. Significant vertebral collapse defined as > 70% of original vertebral height, or a burst, or pedicle fracture;
6. Degenerative scoliosis, defined as Cobb angle > 20° at any level;
7. Pre-existing neurological deficit or radicular pain that is not well defined or unstable;
8. Disabling back pain secondary to causes other than acute fracture;
9. Inability to walk or stand prior to sustaining the vertebral compression fracture;
10. Active systemic or local infection;
11. Known history of Paget's disease, osteomalacia, or any other metabolic bone disease;
12. Morbid obesity defined as a body mass index > 40 kg/m2;
13. Active malignancy. A patient with a history of any invasive malignancy (except nonmelanoma skin cancer), unless treated with curative intent and there has been no clinical signs or symptoms of the malignancy for more than 5 years;
14. Current or recent history (within last 2 years) of substance abuse (e.g., recreational drugs, narcotics, or alcohol);
15. Currently involved in study of another investigational product that may affect outcome;
16. History of psychosocial disorders that could prevent accurate completion of self reporting assessment scales;
17. Pregnant or planning to become pregnant during the study period;
18. Involved in active spinal litigation;
19. Involved in a workers compensation case;
20. Prisoner or ward of the state;
21. Unable to undergo a MRI/CT procedure.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Allograft Tissue; Allograft tissue product for patients with painful vertebral compression fractures	Procedure: Vertebral Body Augmentation; Use allograft tissue in patients with one or two level, thoracic or lumbar T6-L5, vertebral compression fractures.; Device: Manual Surgical Instruments; Lenoss Medical manual surgical access and cavity creation instruments will be used when implanting the allograft tissue.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Evaluate fracture stability assessed via subject- reported pain over time	Subject-reported pain over time using the allograft tissue will be assessed using the Visual Analog Scale (VAS) for back pain on a scale of 0mm (no pain) to 100mm (worst pain imaginable).	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Measure of Physical Disability Assessed via the Roland Morris Disability Questionnaire	The Roland Morris Disability Questionnaire is a widely used health status measure for physical disability caused by low back pain. Scores range from 0 to 24 with higher scores representing higher levels of pain-related disability.	12 months
Measurement of Quality of Life Assessed via the EuroQol Health Outcome Instrument (EQ-5D-3L)	The EQ-5D-3L is a standardized instrument used as a measure of health outcomes. It contains questions in 5 dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression) and provides a simple descriptive profile and single index for health status preference. In addition, there is a Visual Analog Scale (VAS). The VAS is the participant's rating of their health on a scale of 0 "worst imaginable health state" to 100 "best imaginable health state".	12 months
Measurement of Activities of Daily Living Assessed via the Modified Tegner Activity Level Scale	The Modified Tegner Activity Level Scale is designed to measure a patient's activities of daily living, recreation, and competitive sports. The scale includes an assessment of level of activity pre- and post- injury. The scores range from 0 to 10 with a 0 representing sick leave or disability.	12 months
Frequency of Implant Related Complications	The frequency of allograft tissue related complications will be tabulated. Intra-operative complications, surgical time, and any other significant adverse events will be summarized as safety variables. Adverse events will be tabulated by physician's assessment of seriousness, severity, expectedness, the event's causative relation to the allograft tissue or the Access and Cavity Creation instruments, and by elapsed time since surgery. Adverse events that require secondary surgical intervention (SSI) will be flagged.	12 months

Collaborators and Investigators

• Sponsor: Lenoss Medical
• Collaborators: MCRA

Study record dates

Study Major Dates

• Study Start (Actual): June 10, 2019
• Primary Completion (Anticipated): August 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: August 20, 2019
• First Submitted That Met QC Criteria: August 20, 2019
• First Posted (Actual): August 22, 2019

Study Record Updates

• Last Update Posted (Actual): May 14, 2021
• Last Update Submitted That Met QC Criteria: May 12, 2021
• Last Verified: May 1, 2021

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Fractures, Bone; Wounds and Injuries; Fractures, Compression
• Other Study ID Numbers: SP-18-001

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No